Cover Image

Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients

Abstract Background Lumacaftor/Ivacaftor (LUM-IVA), a cystic fibrosis transmembrane conductance regulator (CFTR) protein corrector-potentiator combination, improves lung function and reduces pulmonary exacerbations (PEx) in F508del homozygous CF patients. However, the systemic effects of LUM-IVA out...

Full description

Saved in:

Bibliographic Details
Main Authors:	Karin Yaacoby-Bianu (Author), Zeev Schnapp (Author), Ilana Koren (Author), Anat Ilivitzki (Author), Mohamed Khatib (Author), Nadeem Shorbaji (Author), Michal Shteinberg (Author), Galit Livnat (Author)
Format:	Book
Published:	BMC, 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform
by: Karin Yaacoby-Bianu, et al.
Published: (2023)

Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2-11 years
by: Julian Berges, et al.
Published: (2023)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
by: Connett GJ
Published: (2019)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
by: Patrick O. Hanafin, et al.
Published: (2021)

Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis
by: Stéphanie Bui, et al.
Published: (2021)

Clinical Efficacy and Safety of Ivacaftor/Lumacaftor Combination in Patients with Cystic Fibrosis: International Studies Review
by: Nataliya Yu. Kashirskaya, et al.
Published: (2021)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
by: Eva Choong, et al.
Published: (2022)

Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging
by: Lena Wucherpfennig, et al.
Published: (2023)

Evaluation of the Effectiveness of Using the CFTR Modulator Ivacaftor/Lumacaftor in Children with Cystic Fibrosis in the Sverdlovsk Region (Prospective Cohort Study)
by: Yuliya O. Vasenyova, et al.
Published: (2024)

Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
by: Marika Comegna, et al.
Published: (2021)

CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
by: Olaf Sommerburg, et al.
Published: (2021)

Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats
by: Nicole Reyne, et al.
Published: (2024)

Corrigendum: Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats
by: Nicole Reyne, et al.
Published: (2024)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
by: Argyri Petrocheilou, et al.
Published: (2020)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
by: O’Reilly R, et al.
Published: (2013)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes
by: Francis Christian MD, et al.
Published: (2019)

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
by: Shiferaw D, et al.
Published: (2019)

Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor
by: L. Gómez-Ganda, et al.
Published: (2024)

Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]
by: Shiferaw D, et al.
Published: (2019)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
by: Linus Piehler, et al.
Published: (2023)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor
by: Payal Patel, et al.
Published: (2023)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
by: Nikoletta Kapouni, et al.
Published: (2023)

Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation
by: David Gomez-Pastrana, et al.
Published: (2019)

Ouabain mimics low temperature rescue of F508del-CFTR in cystic fibrosis epithelial cells
by: Donglei eZhang, et al.
Published: (2012)

Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística
by: Paula Del Río Ortega
Published: (2022)

Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística
by: Paula Del Río Ortega
Published: (2022)

Integrative chemogenomic analysis identifies small molecules that partially rescue ΔF508‐CFTR for cystic fibrosis
by: Rachel A. Hodos, et al.
Published: (2021)

Phenotype and Genotype of Two Taiwanese Cystic Fibrosis Siblings and a Survey of Delta F508 in East Asians
by: Chao-Jen Lin, et al.
Published: (2008)

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
by: Renate Kos, et al.
Published: (2022)

Physiologically‐based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patients
by: Magali Amiel, et al.
Published: (2024)

An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
by: Huiya Yuan, et al.
Published: (2021)

SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis
by: Harriet Corvol, et al.
Published: (2018)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
by: Mafalda Bacalhau, et al.
Published: (2023)

Resolution of long standing hypergammaglobulinemic purpura of Waldenström after initiating treatment for cystic fibrosis with Elexacaftor-Tezacaftor-Ivacaftor
by: Kimberly Tantuco, MD, et al.
Published: (2024)

Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study
by: Libor Fila, et al.
Published: (2023)

Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy
by: Frauke Stanke, et al.
Published: (2023)

Prevalência da mutação ΔF508 no gene cystic fibrosis transmembrane conductance regulator em pacientes com fibrose cística em um centro de referência no Brasil Prevalence of ΔF508 mutation in the cystic fibrosis transmembrane conductance regulator gene among cystic fibrosis patients from a Brazilian referral center
by: Andréia Marisa Bieger, et al.
Published: (2012)

The cystic-fibrosis-associated ΔF508 mutation confers post-transcriptional destabilization on the C. elegans ABC transporter PGP-3
by: Liping He, et al.
Published: (2012)

Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor
by: Wolfgang Gruber, et al.
Published: (2024)

Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together
by: Rachel Kinuani, et al.
Published: (2024)